Patents by Inventor Varghese John

Varghese John has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11325904
    Abstract: In various embodiments, compositions and methods are provided for treatment and/or prevention of amyloidogenic diseases. In certain embodiments, the methods entail administering an effective amount of a tropinol ester to a subject in need thereof for prophylactic or therapeutic effect. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In certain embodiments, methods of reducing the risk, lessening the severity, or delaying the progression or onset of a disease characterized by beta-amyloid deposits in the brain of a mammal are also provided. In certain embodiments, methods of directly or indirectly inhibiting the C-terminal cleavage of APP resulting in the formation of APP-C31 peptide and APPneo (AP-P664) in a mammal are provided.
    Type: Grant
    Filed: August 1, 2012
    Date of Patent: May 10, 2022
    Assignee: BUCK INSTITUTE FOR RESEARCH ON AGING
    Inventors: Varghese John, Dale E. Bredesen
  • Patent number: 11247974
    Abstract: There are provided, inter alia, methods and compounds for activating a proliferative program in competent adult chondrocytes.
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: February 15, 2022
    Assignee: The Regents of the University of California
    Inventors: Denis Evseenko, Benjamin J. Van Handel, Varghese John
  • Publication number: 20220041553
    Abstract: Disclosed herein are compounds, compositions, and methods for treating neurodegenerative diseases, such as Alzheimer's disease.
    Type: Application
    Filed: February 11, 2021
    Publication date: February 10, 2022
    Inventors: Barbara Jagodzinska, Jesus Campagna, Johnny Pham, Michael E. Jung, Varghese John, Rammonhan Rao, Dale E. Bredesen, Veena P. Theendakara
  • Patent number: 11243215
    Abstract: In various embodiments methods are provided for identifying and/or quantifying one or more antigens of interest (biomarkers) on the surface of cell- or tissue-specific exosomes.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: February 8, 2022
    Assignee: The Regents of the University of California
    Inventors: Varghese John, Jesus Campagna, Tina Bilousova, Patricia R. Spilman, Peter James Heinzelman, Asa Hatami, Mohammad Parvez Alam
  • Publication number: 20220024935
    Abstract: Pharmaceutical compounds, compositions, methods, and uses therefor are presented using selected triazolopyridines and triazolopyrimidines to inhibit or reduce phosphorylation of tau proteins or that act as antagonists of corticotropin-releasing factor. Viewed from another perspective, compounds, compositions, and methods are presented for treating or preventing symptoms of Alzheimer's disease by inhibiting or reducing the phosphorylation of tau proteins.
    Type: Application
    Filed: September 2, 2021
    Publication date: January 27, 2022
    Inventors: Varghese John, Oleksandr Buzko, Dale Bredesen, Patricia Spilman, Barbara Jagodzinska
  • Patent number: 11142505
    Abstract: Selected compounds, compositions, and methods for inhibiting BACE are presented that have relatively high selectivity towards APP via interaction of the inhibitor with both BACE and APP.
    Type: Grant
    Filed: August 29, 2016
    Date of Patent: October 12, 2021
    Assignee: The Regents of the University of California
    Inventors: Varghese John, Patricia Spilman, Barbara Jagodzinska
  • Patent number: 11091444
    Abstract: In certain embodiments hydantoin compounds are provided herein that are effective to inhibit BACE activity against APP. Without being bound to a particular theory, it is believed the activity of the hydantoins identified herein appears to be associated with binding to BACE and/or to APP particularly when these moieties form a BACE/APP complex. Accordingly, it is believed the compounds described herein represent a new class of compounds designated herein as APP-Binding-BACE Inhibitors (ABBIs) and provide a new mechanism to modulate APP processing. The hydantoins described herein appear to show improved brain permeability and functional BACE inhibition.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: August 17, 2021
    Assignee: BUCK INSTITUTE FOR RESEARCH ON AGING
    Inventors: Varghese John, Dale E. Bredesen
  • Patent number: 11077108
    Abstract: In various embodiments novel allosteric antagonists of the CRFR1 receptor are provided. It discovered that allosteric CRFR1 receptor antagonists are effective to modulate p-Tau levels in Alzheimer's disease (AD) models. In one illustrative embodiment, a compound that is a CRFR1 receptor antagonist is a compound according to the formula or a pharmaceutically acceptable salt, ester, amide, solvate, or prodrug thereof.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: August 3, 2021
    Assignee: The Regents of the University of California
    Inventors: Mohammad Parvez Alam, Varghese John, Barbara Jagodzinska
  • Patent number: 11072592
    Abstract: There are provided, inter alia, methods and compounds for activating a proliferative program in competent adult chondrocytes.
    Type: Grant
    Filed: February 29, 2016
    Date of Patent: July 27, 2021
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Denis Evseenko, Benjamin J. Van Handel, Varghese John
  • Patent number: 10947207
    Abstract: There are provided, inter alia, compounds and methods useful for the treatment of neurological conditions, such as neurological disorders and neurodegenerative diseases, including Alzheimer's Disease.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: March 16, 2021
    Assignee: The Regents of the University of California
    Inventors: Mohammad Parvez Alam, Varghese John, Patricia Spilman, Kanagasabai Vadivel
  • Patent number: 10844071
    Abstract: In certain embodiments compounds corresponding in structure to the formula: are provided that are effective to lower p-tau and/or to prevent or reduce elevation of p-tau, particularly in response to stress (e.g., elevated cortisol levels). The compounds are useful in the treatment or prophylaxis of pathologies characterized by abnormal amyloid plaque and or tangle formation and/or deposition.
    Type: Grant
    Filed: February 21, 2020
    Date of Patent: November 24, 2020
    Assignee: BUCK INSTITUTE FOR RESEARCH ON AGING
    Inventors: Varghese John, Dale E. Bredesen
  • Patent number: 10835546
    Abstract: In certain embodiments APP-specific BACE inhibitors (ASBIs) are provided as well as uses thereof. In certain embodiments methods of preventing delaying the onset of a pre-Alzheimer's condition and/or cognitive dysfunction, and/or ameliorating one or more symptoms of a pre-Alzheimer's condition and/or cognitive dysfunction, or preventing or delaying the progression of a pre-Alzheimer's condition or cognitive dysfunction to Alzheimer's disease are provided where the method involves administering to a subject in need thereof an APP specific BACE inhibitor (ASBI) in an amount sufficient to prevent or delay the onset of a pre-Alzheimer's cognitive dysfunction, and/or to ameliorate one or more symptoms of a pre-Alzheimer's cognitive dysfunction, and/or to prevent or delay the progression of a pre-Alzheimer's cognitive dysfunction to Alzheimer's disease. In certain embodiments the ASBI is a flavonoid (e.g. galangin) or flavonoid progrug (e.g., galangin prodrug).
    Type: Grant
    Filed: June 6, 2019
    Date of Patent: November 17, 2020
    Assignee: BUCK INSTITUTE FOR RESEARCH ON AGING
    Inventors: Varghese John, Dale E. Bredesen
  • Patent number: 10766867
    Abstract: In certain embodiments hydantoin compounds are provided herein that are effective to inhibit BACE activity against APP. Without being bound to a particular theory, it is believed the activity of the hydantoins identified herein appears to be associated with binding to BACE and/or to APP particularly when these moieties form a BACE/APP complex. Accordingly, it is believed the compounds described herein represent a new class of compounds designated herein as APP-Binding-BACE Inhibitors (ABBIs) and provide a new mechanism to modulate APP processing. The hydantoins described herein appear to show improved brain permeability and functional BACE inhibition.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: September 8, 2020
    Assignee: BUCK INSTITUTE FOR RESEARCH ON AGING
    Inventors: Varghese John, Dale E. Bredesen
  • Publication number: 20200270216
    Abstract: Provided herein are compounds of Formula (I) and (II) and their salts, and compositions comprising such compounds that are useful for useful for modulating neutral sphingomyelinase 2 (n-SMase2) in cells. Also disclosed herein are methods of using the disclosed compounds and compositions for inhibiting the spread of Tau seeds from donor cells to recipient cells. Moreover, disclosed herein are methods of using the disclosed compounds and compositions for treating or preventing a neurodegenerative disorder, such as a tauopathy, Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), Lewy body dementia, frontotemporal dementia, and amyotrophic lateral sclerosis (ALS).
    Type: Application
    Filed: September 14, 2018
    Publication date: August 27, 2020
    Inventors: Tina Bilousova, Barbara Jagodzinska, Varghese John
  • Publication number: 20200190094
    Abstract: In certain embodiments compounds (e.g., triazolopyrimidine(s) and/or triazolopyridine(s)) are provided that are effective to lower p-tau and/or to prevent or reduce elevation of p-tau, particularly in response to stress (e.g., elevated cortisol levels). The 5 compounds are useful in the treatment or prophylaxis of pathologies characterized by abnormal amyloid plaque and or tangle formation and/or deposition.
    Type: Application
    Filed: February 21, 2020
    Publication date: June 18, 2020
    Inventors: Varghese JOHN, Dale E. BREDESEN
  • Publication number: 20200148648
    Abstract: In certain embodiments hydantoin compounds are provided herein that are effective to inhibit BACE activity against APP. Without being bound to a particular theory, it is believed the activity of the hydantoins identified herein appears to be associated with binding to BACE and/or to APP particularly when these moieties form a BACE/APP complex. Accordingly, it is believed the compounds described herein represent a new class of compounds designated herein as APP-Binding-BACE Inhibitors (ABBIs) and provide a new mechanism to modulate APP processing. The hydantoins described herein appear to show improved brain permeability and functional BACE inhibition.
    Type: Application
    Filed: January 10, 2020
    Publication date: May 14, 2020
    Inventors: Varghese JOHN, Dale E. BREDESEN
  • Patent number: 10618899
    Abstract: Various [1,2,3]triazolo[4,5-d]pyrimidines are provided that are effective to lower p-tau and/or to prevent or reduce elevation of p-tau, particularly in response to stress (e.g., elevated cortisol levels). The compounds are useful in the treatment or prophylaxis of pathologies characterized by abnormal amyloid plaque and or tangle formation and/or deposition.
    Type: Grant
    Filed: February 17, 2016
    Date of Patent: April 14, 2020
    Assignee: Buck Institute for Research on Aging
    Inventors: Varghese John, Dale E. Bredesen
  • Publication number: 20200030457
    Abstract: In various embodiments deformable nano-scale vehicles (DNV) are provided that are useful for the delivery of therapeutic agents. In certain embodiments the DNVs are capable of transdermal delivery and can additionally cross the blood-brain barrier.
    Type: Application
    Filed: April 2, 2018
    Publication date: January 30, 2020
    Inventors: Varghese John, Ichiro Nishimura, Naren Subbiah, Jesus Campagna, Patricia R. Spilman, Mohammad Parvez Alam
  • Publication number: 20200017449
    Abstract: In certain embodiments hydantoin compounds are provided herein that are effective to inhibit BACE activity against APP. Without being bound to a particular theory, it is believed the activity of the hydantoins identified herein appears to be associated with binding to BACE and/or to APP particularly when these moieties form a BACE/APP complex. Accordingly, it is believed the compounds described herein represent a new class of compounds designated herein as APP-Binding-BACE Inhibitors (ABBIs) and provide a new mechanism to modulate APP processing. The hydantoins described herein appear to show improved brain permeability and functional BACE inhibition.
    Type: Application
    Filed: February 8, 2019
    Publication date: January 16, 2020
    Inventors: Varghese John, Dale E. Bredesen
  • Patent number: 10449177
    Abstract: The invention provides compositions and methods for the treatment of mild cognitive impairment (MCI), and for inhibiting, reducing, delaying and/or preventing the progression of MCI to Alzheimer's disease. The methods entail administering an effective amount of one or more compounds selected from the group consisting of tropisetron, disulfuram, honokiol and nimetazepam. The methods also are useful for prophylactic and therapeutic treatment of amyloidogenic diseases, including Alzheimer's disease.
    Type: Grant
    Filed: August 19, 2011
    Date of Patent: October 22, 2019
    Assignee: Buck Institute for Research on Aging
    Inventors: Varghese John, Dale E. Bredesen